Department of Gynecology Oncology, Affiliated Tumor Hospital of Harbin Medical University, Harbin, China.
J Surg Oncol. 2013 Jun;107(8):847-52. doi: 10.1002/jso.23336. Epub 2013 Apr 22.
The overexpressed in lung cancer 1 (OLC1), a novel tumor associated gene, is upregulated in several carcinomas. The purpose of this study was to determine whether increased expression of OLC1 is associated with epithelial ovarian carcinoma (EOC) that diagnosed in patients.
OLC1 expression was assayed in 20 normal ovarian and 139 ovarian cancer's specimens by Western blotting and immunohistochemical staining (IHC). Univariate and multivariate analysis were performed to determine the association between OLC1 expression and prognosis.
Western blotting analysis demonstrated that OLC1 was overexpressed in ovarian cancers, and immunohistochemistry results revealed that 63 patients had increased level of OLC1. The 5-year overall survival (OS) rates of patients with high OLC1 expression and low OLC1 expression were 24.8% and 75.2%, respectively (hazard ratio: 21.43, 95% CI: 2.54, 7.12, P < 0.0001). The 5-year progression-free survival (PFS) rates were 30.1% for patients in the high-expression group and 69.9% for patients in the low OLC1 expression group (hazard ratio: 17.04, 95% CI: 0.33, 5.96, P < 0.0001).
OLC1 over-expression is an important factor in epithelial ovarian carcinoma prognosis and can be a potential biomarker for ovarian carcinoma.
肺癌相关基因 1（OLC1）在多种癌症中呈过表达，是一种新型肿瘤相关基因。本研究旨在确定 OLC1 的表达增加是否与患者诊断的上皮性卵巢癌（EOC）有关。
通过 Western blot 和免疫组织化学染色（IHC）检测 20 例正常卵巢和 139 例卵巢癌标本中的 OLC1 表达。采用单因素和多因素分析来确定 OLC1 表达与预后之间的关系。
Western blot 分析表明 OLC1 在卵巢癌中过表达，免疫组化结果显示 63 例患者 OLC1 水平升高。高 OLC1 表达和低 OLC1 表达患者的 5 年总生存率（OS）分别为 24.8%和 75.2%（风险比：21.43，95%CI：2.54，7.12，P < 0.0001）。高表达组患者的 5 年无进展生存率（PFS）为 30.1%，低 OLC1 表达组患者的 5 年无进展生存率为 69.9%（风险比：17.04，95%CI：0.33，5.96，P < 0.0001）。
OLC1 过表达是上皮性卵巢癌预后的重要因素，可能成为卵巢癌的潜在生物标志物。
